

BAŞ BOYUN KANSERLERİ

Şükriye DADALI ¹
Mustafa ŞEN ²
Fuat GÜLDOĞUŞ ³

ÖZET

Üst solunum ve sindirim kanalı ile cildinde ortaya çıkan baş boyun kanserleri, en yaygın altıncı kanser türüdür. Hastanın yaşam kalitesi üzerinde doğrudan etkili olan ağrı, baş boyun kanserli hastalarda sıktır. Ağrı, kanserin kendisine ve tedavilerine bağlı olabileceği gibi kanserle ilgisi de olmayabilir. Kanser ağrısı, kaynağına göre genel olarak nosiseptif, nöropatik veya mikst tip ağrı olarak sınıflandırılmaktadır. Oral ve orofaringeal yerleşim, ileri evre, multimodal onkolojik tedavi, bazı psikososyal faktörler artmış ağrı skorları ile ilişkili bulunmuştur. Bu hastalardaki ağrının türünün ve nedeninin değerlendirilmesi, optimal ağrı yönetiminin planlanmasında belirleyicidir. Klinik bir ağrı tanısı için, anamnez, kapsamlı fizik ve nörolojik muayene yanı sıra hastanın psikososyal değerlendirmesi gereklidir. Ağrı şiddetinin standardize değerlendirme araçları yardımıyla düzenli takibi, etkili ve bireyselleştirilmiş tedaviye yönelik ilk adımdır. Kanser hastasında ağrının boyutlarını değerlendirmek için McGill Ağrı Anketi kısa formu, nöropatik belirti ve semptomları değerlendirmek için LANSS anketi ve DN4 testi kullanılabilir. Baş boyun kanseri hastalarında ağrı çok faktörlüdür, bu nedenle ağrı yönetiminde antineoplastik, farmakolojik, girişimsel ağrı tedavisi ve tamamlayıcı yöntemlerin kombinasyonunu içeren kapsamlı ve multimodal bir yaklaşım gereklidir. Ağrı tedavisi temel olarak sistemik analjezikler, adjuvan ilaçlar ve opioidleri aşamalı bir şekilde kullanan, girişimsel tekniklerle birleştirilmiş, DSÖ'nün kanser ağrı basamak tedavisine ve farmakolojik yönetim ilkelerine dayanmaktadır. Kanser ağrısına yönelik kılavuzlarda, ağrı yönetiminin bireye özel planlanması ve hastanın onkolojik tedavi planına entegre edilmesi önerilmektedir. Baş ve boyun kanserli hastaların %10-20'sinde farmakolojik tedavi ile ağrı iyileşmesi yeterli olmayabilir veya tolere edilemeyen yan etkiler gelişebilir. Bu hastalarda, girişimsel yöntemler tek başına veya sistemik tedavi ile birlikte kullanıldığında ağrı kontrolü sağlayabilir. Girişimsel yöntemler arasında sinir blokları, nöromodülasyon, nörodestrüktif teknikler ve intraspinal ilaç sistemleri bulunmaktadır. Bilişsel, davranışsal, fiziksel, beslenme yöntem-

¹ Uzm. Dr., Ankara Şehir Hastanesi, Algoloji Bölümü, sukriyedadali@yahoo.com

² Arş Gör. Dr., Osmangazi Üniversitesi Tıp Fakültesi, Algoloji BD., mustafa.sen@ogu.edu.tr

³ Prof. Dr., Ondokuz Mayıs Üniversitesi Tıp Fakültesi, Algoloji BD., Başkanı fuatg@omu.edu.tr

KAYNAKLAR

1. Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. WHO, International Agency for Research on Cancer Web site (2012). 2017. [http:// globocan.iarc.fr/Pages/fact-sheets-cancer.aspx](http://globocan.iarc.fr/Pages/fact-sheets-cancer.aspx).
2. Winquist E., Agbassi C., Meyers BM. et al. and the Head and Neck Disease Site Group: Systemic therapy in the curative treatment of head- and-neck squamous cell cancer: Cancer Care Ontario clinical practice guideline. *Current Oncology*. 2017 Apr.; 24 (2): e157–e162.
3. Bhatnagar S., Gupta M. Evidence-Based Clinical Practice Guidelines for Interventional Pain Management in Cancer Pain. *Indian Journal of Palliative Care*: May-Aug 2015;21/2. doi:10.4103/0973-1075.156466
4. Blasco MA., Cordero J., Dunder Y. Chronic Pain Management in Head and Neck Oncology. *Otolaryngol Clin N Am*. 2020. <https://doi.org/10.1016/j.otc.2020.05.015>
5. Van den beuken-van everdingen MH, De rijke JM, Kessels AG, et al. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. *Ann Oncol* 2007;18(9):1437–49.
6. Chaplin JM, Morton RP. A prospective, longitudinal study of pain in head and neck cancer patients. *Head Neck* 1999; 21:531-7
7. Ortiz VMS, Ornelas GEA, Cantisani JAF et al. Interventional techniques for head and neck cancer pain. Chapter from the book *Diagnosis and Management of Head and Neck Cancer*. 2017;6:97-107. DOI: 10.5772/intechopen.69655.
8. Grond S, Zech D, Lynch J et al. Validation of world health organization guidelines for pain relief in head and neck cancer. A prospective study. *Ann Otol Rhinol Laryngol* 1993; 102:342-8.
9. Potter J, Higginson IJ, Scadding JW et al. Identifying neuropathic pain in patients with head and neck cancer: Use of the leads assessment of neuropathic symptoms and signs scale. *J R Soc Med* 2003; 96:379-83.
10. Kou P, Williams JE. Pain control in head and neck cancer. In: Agulnik M, editor. *Head and Neck Cancer*. InTech; 2012. p. 351-71.
11. Grond S, Zech D, Diefenbach C et al. Assessment of cancer pain: A prospective evaluation in 2266 cancer patients referred to a pain service. *Pain* 1996; 64:107-14.
12. Epstein JB, Wilkie DJ, Fisher DJ et al. Neuropathic and nociceptive pain in head and neck cancer patients receiving radiation therapy. *Head Neck Oncol* 2009; 1:26.
13. Ghei A, Khot S. Pain management in patients with head and neck carcinoma. *Otolaryngol Clin* 2010; 2:69-75.
14. Bossi P, Massimo G, Argenone A et al. Is pain part of a systemic syndrome in head and neck cancer? *Supportive Care in Cancer* 2020; 28, pages 451–459.
15. Mehio AK, Shah SN. Alleviating head and neck pain. *Otolaryngol Clin N Am* 42 (2009) 143–159.
16. Grond S, et al. Validation of World Health Organization guidelines for pain relief in head and neck cancer. A prospective study. *Ann Otol Rhinol Laryngol*. 1993;102(5):342–8.
17. Trotter PB, et al. Pharmacological and other interventions for head and neck cancer pain: a systematic review. *J Oral Maxillofac Res*. 2012;3(4):e1.
18. Binczak M, et al. Management of somatic pain induced by head-and-neck cancer treatment: definition and assessment guidelines of the French Oto-Rhino-Laryngology- Head and Neck Surgery Society. *Eur Ann Otorhinolaryngol Head Neck Dis*. 2014;131(4):243–7.
19. International Association for the Study of Pain. IASP terminology. Available at: <https://www.iasp-pain.org/Education/Content.aspx?ItemNumber51698>. 2019.
20. Villaret D, Weymuller E. Pain caused by cancer of the head and neck. In: Loeser J, Butler S, Chapman R, editors. *Bonica's management of pain*. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 948–65.
21. Puttanniah V., Zininberg EV., Head and neck cancer pain In: Amitabh Gulati A., Puttanniah V., Bruel BM., Rosenberg WS., Hung JC. Editors: *Essentials of Interventional Cancer Pain Management*. ©Springer Nature Switzerland AG 2019: Part III-8:55-62. <https://doi.org/10.1007/978-3-319-99684-4>
22. Nencini S, Ivanusic JJ. The physiology of bone pain. How much do we really know? *Front Physiol Front Physiol*. 2016; 7:157. n. pag. Web.
23. Mach DB, Rogers SD, Sabino MC, Luger NM, Schwei MJ, Pomonis JD, Keyser CP, Clohisy DR, Adams DJ, O'Leary P, Mantyh PW. Origins of skeletal pain: sensory and sympathetic innervation of the mouse femur. *Neuroscience*. 2002;113(1):155–66. Web.
24. Jimenez-Andrade JM, Mantyh WG, Bloom AP, et al. A phenotypically restricted set of primary afferent nerve fibers innervate the bone versus skin: therapeutic opportunity for treating skeletal pain. *Bone*. 2010;46(2):306–13. Web.
25. Ohtori S, Orita S, Yamashita M, et. al. Existence of a neuropathic pain component in patients with osteoarthritis of the knee. *Yonsei Med J Yonsei Med J*. 2012;53(4):801. Web.
26. Roodman GD. Mechanisms of bone metastasis. *N Engl J Med* 2004;350: 1655–64.
27. Jaeckle K. Neurologic manifestations of neoplastic and radiation-induced Plexopathies. *Semin Neurol*. 2010;30(03):254–62. Web.
28. Elliott K, Foley KM. Neurologic pain syndromes in patients with cancer. *Crit Care Clin* 1990; 6:393–420.
29. Bogduk N, Marsland A. The cervical zygapophysial joints as a source of neck pain. *Spine* 1988; 13:607–10.
30. Bhaskar AK, Simpson KH. Interventional management of pain in cancer and palliative care. *Medicine. Physical problems*. 2020; 48:1.9-13
31. Mirabile A, et al. Pain management in head and neck cancer patients undergoing chemo-radiotherapy: clinical practical recommendations. *Crit Rev Oncol Hematol*. 2016; 99:100–6.
32. Riley P, Glennly AM, Worthington HV, et al. Interventions for preventing oral mucositis in patients with cancer receiving treatment: oral cryotherapy. *Cochrane Database Syst Rev*. 2015;(12). Art. No.: CD011552.
33. Pandya JA, et al. Post-radiation changes in oral tissues – an analysis of cancer irradiation cases. *South Asian J*

- Cancer. 2014;3(3):159–62.
34. Henriques de Figueiredo B, Grégoire V. How to minimize morbidity in radiotherapy of pharyngolaryngeal tumors? *Curr Opin Otolaryngol Head Neck Surg*. 2016;24(2):163–9.
 35. Straub JM, et al. Radiation-induced fibrosis: mechanisms and implications for therapy. *J Cancer Res Clin Oncol*. 2015;141(11):1985–94.
 36. Chan JY, et al. Shoulder dysfunction after selective neck dissection in recurrent nasopharyngeal carcinoma. *Otolaryngol Head Neck Surg*. 2015;153(3):379–84.
 37. Lauchlan DT, McCaul JA, McCarron T. Neck dissection and the clinical appearance of post-operative shoulder disability: the post-operative role of physiotherapy. *Eur J Cancer Care*. 2008;17(6):542–8. [PubMed].
 38. Rogers SN, Ferlito A, Pellitteri PK, Shaha AR, et al. Quality of life following neck dissections. *Acta Otolaryngol*. 2004;124(3):231–6. [PubMed].
 39. Terrell JE, et al. Pain, quality of life, and spinal accessory nerve status after neck dissection. *Laryngoscope*. 2000;110(4):620–6.
 40. Epstein JB, Wilkie DJ, Fischer DJ, et al. Neuropathic and nociceptive pain in head and neck cancer patients receiving radiation therapy. *Head Neck Oncol*. 2009; 1:26.
 41. Borggrevén PA, Verdonck-de Leeuw IM, Muller MJ, et al. Quality of life and functional status in patients with cancer of the oral cavity and oropharynx: pretreatment values of a prospective study. *Eur Arch Otorhinolaryngol* 2007;264(6):651–7.
 42. Infante-Cossio P, Torres-carranza E, Cayuela A, et al. Quality of life in patients with oral and oropharyngeal cancer. *Int J Oral Maxillofac Surg* 2009;38(3):250–5.
 43. Singer S, Wollbrück D, Wulke C, et al. Validation of the EORTC QLQ-C30 and EORTC QLQ-H&N35 in patients with laryngeal cancer after surgery. *Head Neck* 2009;31(1):64–76.
 44. Korfage A, Schoen PJ, Raghoobar GM, et al. Five-year follow-up of oral functioning and quality of life in patients with oral cancer with implant-retained mandibular overdentures. *Head Neck* 2011;33(6):831–9.
 45. Chan JY, Lua LL, Starmer HH, et al. The relationship between depressive symptoms and initial quality of life and function in head and neck cancer. *Laryngoscope* 2011;121(6):1212–8.
 46. Zwahlen RA, Dannemann C, Graetz KW, et al. Quality of life and psychiatric morbidity in patients successfully treated for oral cavity squamous cell cancer and their wives. *J Oral Maxillofac Surg* 2008;66(6):1125–32.
 47. Fallon M, Giusti R, Aielli F, et al. on behalf of the ESMO Guidelines Committee. Management of cancer pain in adult patients: ESMO clinical practice guidelines. *Annals of oncology*. 2018; 29 (4): 166–191.
 48. Cleeland CS, Ryan KM. Pain assessment: global use of the brief pain inventory. *Ann Acad Med Singapore*. 1994; 23:129–38.
 49. Gauthier LR, Young A, Dworkin RH, et al. Validation of the short-form McGill pain questionnaire-1 in younger and older people with cancer pain. *J Pain*. 2014; 15:756–70.
 50. Bouhassira D, Attal N, Alchaar H, et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). *Pain*. 2005; 114:29–36.
 51. Bennett M. The LANSS pain scale: the Leeds assessment of neuropathic symptoms and signs. *Pain*. 2001; 92:147–57.
 52. Zech DF, Grond S, Lynch J, et al. Validation of World Health Organization guidelines for cancer pain relief: a 10-year prospective study. *Pain* 1995;63(1):65–76.
 53. Swarm RA, Paice JA, Anghelescu DL, et al. Adult Cancer Pain, Version 3.2019, National Comprehensive Cancer Network (NCCN), Clinical Practice Guidelines in Oncology. Volume 17: Issue 8. Aug 2019. DOI: <https://doi.org/10.6004/jnccn.2019.0038>.
 54. Mastsumoto S. Thermographic assessment of the sympathetic blockade by stellate ganglion block (20); Comparison between C7-SGB and C6-SGB in 20 healthy volunteers. *Masui*. 1991; 40:692–701.
 55. Prasanna A, Murthy PS. Sphenopalatine ganglion block and pain of cancer. *J Pain Symptom Manag*. 1993;8(3):125.
 56. Piagkou M, Demesticha T, Troupis T, et al. The pterygopalatine ganglion and its role in various pain syndromes: from anatomy to clinical practice. *Pain Pract*. 2012; 12:399–412.
 57. Day M. Neurolysis of the trigeminal and sphenopalatine ganglions. *Pain Pract*. 2001; 1:171–82.
 58. Levin M. Nerve blocks in the treatment of headache. *Neurotherapeutics*. 2010;7(2):197–203.
 59. Dach F, et al. Nerve block for the treatment of headaches and cranial neuralgias – a practical approach. *Headache*. 2015;55(Suppl 1):59–71.
 60. Kohase H, Umino M, Shibaji T, et al. Application of a mandibular nerve block using an indwelling catheter for intractable cancer pain. *Acta Anaesthesiol Scand*. 2004;48(3):382–3.
 61. Klessinger S. The benefit of therapeutic medial branch blocks after cervical operations. *Pain Physician*. 2010;13(6):527–34.
 62. Sist T, Miner M, Lema M. Characteristics of post-radical neck pain syndrome: a report of 25 cases. *J Pain Symptom Manag*. 1999;18(2):95–102.
 63. Stubblefield MD, Levine A, Custodio CM, et al. The role of botulinum toxin type A in the radiation fibrosis syndrome: a preliminary report. *Arch Phys Med Rehabil*. 2008;89(3):417–21.
 64. DeSantana JM, Walsh DM, Vance C, et al. Effectiveness of transcutaneous electrical nerve stimulation for treatment of hyperalgesia and pain. *Curr Rheumatol Rep*. 2008;10(6):492–9.
 65. DeSantana JM, Santana-Filho VJ, Guerra DR, et al. Hypoalgesic effect of the transcutaneous electrical nerve stimulation following inguinal herniorrhaphy: a randomized, controlled trial. *J Pain*. 2008; 9:623–9.
 66. Solak O, Turna A, Pekcolaklar A, et al. Transcutaneous electric nerve stimulation for the treatment of postthoracotomy pain: a randomized prospective study. *Thorac Cardiovasc Surg*. 2007; 55:182–5.
 67. Vijayan A, et al. Prospective phase II study of the efficacy of transcutaneous electrical nerve stimulation

- in post-radiation patients. *Clin Oncol (R Coll Radiol)*. 2014;26(12):743-7.
68. Lakshman AR, et al. Evaluation of effect of transcutaneous electrical nerve stimulation on salivary flow rate in radiation induced xerostomia patients: a pilot study. *J Cancer Res Ther*. 2015;11(1):229-33.
 69. Maniam R, Kaye AD, Vadivelu N, et al. Facial pain update: advances in neurostimulation for the treatment of facial pain. *Curr Pain Headache Rep*. 2016;20(4):24.
 70. Smith TJ, et al. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. *J Clin Oncol*. 2002;20(19):4040-9.
 71. Appelgren L, Janson M, Nitescu P, et al. Continuous intracisternal and high cervical intrathecal bupivacaine analgesia in refractory head and neck pain. *Anesthesiology*. 1996;84(2):256-72.
 72. Lundborg C et al. High intrathecal bupivacaine for severe pain in the head and neck. *Acta Anaesth Scand*. 2009;53(7):908-13.
 73. Datta S, Pai UT. Interventional approaches to management of pain of oral cancer. *Oral Maxillofac Surg Clin North Am*. 2006;18(4):627-41.
 74. Lazorthes YR, Sallerin BA, Verdé JC. Intracerebroventricular administration of morphine for control of irreducible cancer pain. *Neurosurgery*. 1995;37(3):422-8.
 75. Kanpolat Y. Percutaneous cordotomy and trigeminal tractotomy-nucleotomy. *Neurosurg*. 2015.
 76. Molassiotis A, Ozden G, Platin N, et al. Complementary and alternative medicine use in patients with head and neck cancers in Europe. *Eur J Cancer Care* 2006;15(1):19-24.
 77. Matovina C, Birkeland AC, Zick S, et al. Integrative medicine in head and neck cancer. *Otolaryngol Head Neck Surg* 2017;156(2):228-37.
 78. Pfister DG, Cassileth BR, Deng GE, et al. Acupuncture for pain and dysfunction after neck dissection: results of a randomized controlled trial. *J Clin Oncol* 2010;28(15):2565-70.
 79. Riley P, Glenny AM, Worthington HV, et al. Interventions for preventing oral mucositis in patients with cancer receiving treatment: oral cryotherapy. *Cochrane Database Syst Rev* 2015: Cd011552. <https://www.ncbi.nlm.nih.gov/pubmed/26695736>.
 80. Idayu Mat Nawi R, Lei Chui P, et al. Oral cryotherapy: Prevention of oral mucositis and pain among patients with colorectal cancer undergoing chemotherapy. *Clin J Oncol Nurs* 2018; 22:555-560.
 81. Cai Q, Huang H, Sun X, et al. Efficacy and safety of transdermal fentanyl for treatment of oral mucositis pain caused by chemotherapy. *Expert Opin Pharmacother* 2008;9(18):3137-44.
 82. Kataoka T, Kiyota N, Shimada T, et al. Randomized trial of standard pain control with or without gabapentin for pain related to radiation induced mucositis in head and neck cancer. *Auris Nasus Larynx* 2016; 43:677-684. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26992271>.
 83. Bar Ad V, Weinstein G, Dutta PR, et al. Gabapentin for the treatment of pain syndrome related to radiation-induced mucositis in patients with head and neck cancer treated with concurrent chemoradiotherapy. *Cancer* 2010; 116:4206-4213. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20564146>.
 84. Kwong KK. Prevention and treatment of oropharyngeal mucositis following cancer therapy: are there new approaches? *Cancer Nurs* 2004; 27:183-205. <https://www.ncbi.nlm.nih.gov/pubmed/15238805>.
 85. Eilers J, Harris D, Henry K, Johnson LA. Evidence-based interventions for cancer treatment-related mucositis: putting evidence into practice. *Clin J Oncol Nurs* 2014;18 Suppl:80-96. <https://www.ncbi.nlm.nih.gov/pubmed/25427611>.
 86. Chitapanarux I, Tungkasamit T, Petsuksiri J, et al. Randomized control trial of benzydamine HCl versus sodium bicarbonate for prophylaxis of concurrent chemoradiation-induced oral mucositis. *Support Care Cancer* 2018; 26:879-886.
 87. Swarm RA, Youngwerth JM, Agne JL, et al. Adult cancer pain. *Comprehensive Cancer Network, Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Version 1.2022*.
 88. Erdine S, Racz G, Noe C. Somatic blocks of the head and neck. In: Raj P, et al., editors. *Interventional pain management, imageguided procedures*. Philadelphia: Saunders; 2008.
 89. Stubblefield MD. Radiation fibrosis syndrome: neuromuscular and musculoskeletal complications in cancer survivors. *PM&R*. 2011.
 90. Peck D, Echezona GJ. Treatment considerations for cancer pain syndromes In: Amitabh Gulati A, Puttaniah V, Bruel BM, Rosenberg WS, Hung JC. Editors: *Essentials of Interventional Cancer Pain Management*. ©Springer Nature Switzerland AG 2019: Part IV-21:218. <https://doi.org/10.1007/978-3-319-99684-4>.